Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

FGF401, A First-In-Class Highly Selective and Potent FGFR4 Inhibitor for the Treatment of FGF19-Driven Hepatocellular Cancer.

Weiss A, Adler F, Buhles A, Stamm C, Fairhurst RA, Kiffe M, Sterker D, Centeleghe M, Wartmann M, Kinyamu-Akunda J, Schadt HS, Couttet P, Wolf A, Wang Y, Barzaghi-Rinaudo P, Murakami M, Kauffmann A, Knoepfel T, Buschmann N, Leblanc C, Mah R, Furet P, Blank J, Hofmann F, Sellers WR, Graus Porta D.

Mol Cancer Ther. 2019 Dec;18(12):2194-2206. doi: 10.1158/1535-7163.MCT-18-1291. Epub 2019 Aug 13.

PMID:
31409633
2.

2-Formylpyridyl Ureas as Highly Selective Reversible-Covalent Inhibitors of Fibroblast Growth Factor Receptor 4.

Knoepfel T, Furet P, Mah R, Buschmann N, Leblanc C, Ripoche S, Graus-Porta D, Wartmann M, Galuba I, Fairhurst RA.

ACS Med Chem Lett. 2018 Feb 1;9(3):215-220. doi: 10.1021/acsmedchemlett.7b00485. eCollection 2018 Mar 8.

3.

Approaches to selective fibroblast growth factor receptor 4 inhibition through targeting the ATP-pocket middle-hinge region.

Fairhurst RA, Knoepfel T, Leblanc C, Buschmann N, Gaul C, Blank J, Galuba I, Trappe J, Zou C, Voshol J, Genick C, Brunet-Lefeuvre P, Bitsch F, Graus-Porta D, Furet P.

Medchemcomm. 2017 Jun 8;8(8):1604-1613. doi: 10.1039/c7md00213k. eCollection 2017 Aug 1.

4.

Bioorthogonal Probes for the Study of MDM2-p53 Inhibitors in Cells and Development of High-Content Screening Assays for Drug Discovery.

D'Alessandro PL, Buschmann N, Kaufmann M, Furet P, Baysang F, Brunner R, Marzinzik A, Vorherr T, Stachyra TM, Ottl J, Lizos DE, Cobos-Correa A.

Angew Chem Int Ed Engl. 2016 Dec 23;55(52):16026-16030. doi: 10.1002/anie.201608568. Epub 2016 Nov 22.

PMID:
27874234
5.

Discovery of a Dihydroisoquinolinone Derivative (NVP-CGM097): A Highly Potent and Selective MDM2 Inhibitor Undergoing Phase 1 Clinical Trials in p53wt Tumors.

Holzer P, Masuya K, Furet P, Kallen J, Valat-Stachyra T, Ferretti S, Berghausen J, Bouisset-Leonard M, Buschmann N, Pissot-Soldermann C, Rynn C, Ruetz S, Stutz S, Chène P, Jeay S, Gessier F.

J Med Chem. 2015 Aug 27;58(16):6348-58. doi: 10.1021/acs.jmedchem.5b00810. Epub 2015 Aug 5.

PMID:
26181851
6.

Gateway synthesis of daphnane congeners and their protein kinase C affinities and cell-growth activities.

Wender PA, Buschmann N, Cardin NB, Jones LR, Kan C, Kee JM, Kowalski JA, Longcore KE.

Nat Chem. 2011 Jun 19;3(8):615-9. doi: 10.1038/nchem.1074.

7.

Studies on oxidopyrylium [5+2] cycloadditions: toward a general synthetic route to the C12-hydroxydaphnetoxins.

Wender PA, Bi FC, Buschmann N, Gosselin F, Kan C, Kee JM, Ohmura H.

Org Lett. 2006 Nov 9;8(23):5373-6.

PMID:
17078721
8.

Comparison of DNA ploidy status and DNA ploidy-related parameters in malignant melanoma tissue microarrays and full sections.

Korabiowska M, Cordon-Cardo C, Buschmann N, Stachura J, Fischer G, Brinck U.

Hum Pathol. 2004 Jul;35(7):887-91.

PMID:
15257554
9.

Comparative study of p63 and p53 expression in tissue microarrays of malignant melanomas.

Brinck U, Ruschenburg I, Di Como CJ, Buschmann N, Betke H, Stachura J, Cordon-Cardo C, Korabiowska M.

Int J Mol Med. 2002 Dec;10(6):707-11.

PMID:
12429996
10.

A new approach to (-)-swainsonine by ruthenium-catalyzed ring rearrangement.

Buschmann N, Rückert A, Blechert S.

J Org Chem. 2002 Jun 14;67(12):4325-9.

PMID:
12054970
11.

Novel teststrip with increased accuracy.

Starp H, Buschmann N, Cammann K.

Fresenius J Anal Chem. 2000 Sep-Oct;368(2-3):203-7.

PMID:
11220580
12.

Synthesis and Application of a Permanently Immobilized Olefin-Metathesis Catalyst.

Schürer SC, Gessler S, Buschmann N, Blechert S.

Angew Chem Int Ed Engl. 2000 Nov 3;39(21):3898-3901. doi: 10.1002/1521-3773(20001103)39:21<3898::AID-ANIE3898>3.0.CO;2-X. No abstract available.

PMID:
29711688
13.

Relevance of ploidy related parameters for prognosis in malignant fibrous histiocytomas.

Brinck U, Korabiowska M, Buschmann N, Stachura J, Ruschenburg I, Cordon-Cardo C, Schauer A.

Anticancer Res. 1999 Nov-Dec;19(6B):5211-6.

PMID:
10697537

Supplemental Content

Loading ...
Support Center